In regard to the slowness in bringing in some of the new diabetic treatments and some of the new cancer treatments that you've described today, do you view that as budgetary constraint or do you view it as a slow bureaucratic process in Pharmac? What do you view as the reasons it is not more timely? Have you provided any recommendations to Pharmac on how to improve the timeliness?
On February 14th, 2017. See this statement in context.